GlassScriptPhysician profile
Shuya Wu
NPI 1982947958
$9,877.70
in general payments reported to CMS, 2019-2025
33 companies · $2,814 in 2025
The $2,814 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $919 · 2020: $203 · 2021: $730 · 2022: $1,580 · 2023: $1,463 · 2024: $2,168 · 2025: $2,814.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,411 · Consulting Fee: $22.10 · Education: $11.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,411.34 |
| Consulting Fee | $22.10 |
| Education | $11.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,666.71 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Genzyme Corporation | $1,476.58 | 2019-2025 | |
| Csl Behring | $1,130.42 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $932.48 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $758.72 | 2019-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $596.24 | 2021-2025 | Takhzyro, Cuvitru |
| Genentech USA, INC. | $487.34 | 2019-2025 | Xolair |
| Pfizer INC. | $451.17 | 2019-2025 | |
| Blueprint Medicines Corporation | $273.97 | 2023-2025 | Ayvakit |
| Amgen INC. | $265.62 | 2021-2025 | Tezspire |
| Optinose US, INC. | $238.83 | 2019-2025 | |
| Grifols USA, LLC | $231.19 | 2022-2025 | Prolastin-C Liquid, Xembify |
| Novartis Pharmaceuticals Corporation | $215.29 | 2019-2025 | |
| Ars Pharmaceuticals Operations, INC. | $194.22 | 2025 | Neffy |
| Pharming Healthcare, INC. | $153.83 | 2019-2025 | Ruconest |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $145.18 | 2021-2024 | Auvi-Q |
| Boehringer Ingelheim Pharmaceuticals, INC. | $90.71 | 2019-2022 | |
| Biocryst US Sales Co., LLC | $90.68 | 2022-2025 | Orladeyo |
| Alk-Abello, INC | $58.73 | 2019-2020 | |
| Cycle Pharmaceuticals INC | $51.78 | 2025 | Sajazir |
| Shire North American Group INC | $47.67 | 2019 | |
| Phadia US INC. | $44.91 | 2023-2024 | Immunocap |
| Adma Biomanufacturing LLC | $44.35 | 2022-2024 | |
| Ionis Pharmaceuticals, INC. | $37.92 | 2025 | Dawnzera |
| Merck Sharp & Dohme LLC | $32.26 | 2021-2023 | |
| Azurity Pharmaceuticals, INC. | $32.02 | 2025 | Alvesco |
| Paratek Pharmaceuticals, INC. | $23.03 | 2025 | Xhance |
| Octapharma USA, INC. | $22.00 | 2022 | |
| Uswm, LLC | $20.25 | 2021 | |
| Hikma Pharmaceuticals USA | $19.41 | 2025 | Ryaltris |
| Covis Pharma Gmbh | $18.54 | 2022 | |
| Jubilant Hollisterstier LLC | $13.61 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shuya Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.